Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Nivolumab improves survival in 80% of trial participants with common…
Share on Pinterest Researchers investigated the 5-year outcome of an immunotherapy drug on early-stage lung cancer. lung cancer 80% of those who took the immunotherapy drug survived after 5 years, whereas survival rates from standard treatments are 36–68%. Further clinical…
English